Sussell J, Singh Jhuti G, Antao V, Herrera-Restrepo O, et al. Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States. Am J Clin Oncol 2021;44:340-349.
PMID: 34151896